(19)
(11) EP 2 860 192 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
22.04.2015 Bulletin 2015/17

(43) Date of publication A2:
15.04.2015 Bulletin 2015/16

(21) Application number: 14196972.5

(22) Date of filing: 12.10.2006
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
C07K 16/40(2006.01)
G01N 33/574(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 12.10.2005 US 725297 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06806243.9 / 1945671

(71) Applicant: MorphoSys AG
82152 Martinsried/München (DE)

(72) Inventors:
  • Tesar, Michael
    86316 Friedberg (DE)
  • Jäger, Ute
    81667 München (DE)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München
80538 München (DE)

   


(54) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38


(57) The invention provides a human antibody that is specific for CD38. The antibody of the invention has the ability to bind to CD38 of minipig origin and induce, by cross-linking, specific killing of cells, in particular tumor cells, expressing CD38. The invention further provides uses of this antibody for treating various disorders and conditions associated with undesired presence of CD38+ cells, including hematological and inflammatory diseases. The invention also provides diagnostic compositions and methods based on detecting the presence of CD38 in a tissue or a cell of minipig origin contacted with the antibody of the invention.





Search report















Search report